October 9, 2014

CEO of Cambridge’s newest biotech, Oryzon, sets sights on expansion

A Spanish biotech firm with drugs in development for cancer and Alzheimer’s has opened its first U.S. site in Cambridge, and its CEO is hoping to grow quickly.

CEO Carlos Buesa of Oryzon Genomics said in an interview today that not only does he plan to eventually increase the headcount at 245 First St. in Kendall Square to around 10, but he may consider moving its global headquarters here and going public at some point.